209 related articles for article (PubMed ID: 35115614)
21. Hepatic insulin clearance is increased in patients with high HbA1c type 2 diabetes: a preliminary report.
Okura T; Fujioka Y; Nakamura R; Anno M; Ito Y; Kitao S; Matsumoto K; Shoji K; Sumi K; Matsuzawa K; Izawa S; Okura H; Ueta E; Noma H; Kato M; Imamura T; Taniguchi SI; Yamamoto K
BMJ Open Diabetes Res Care; 2020 Apr; 8(1):. PubMed ID: 32354719
[TBL] [Abstract][Full Text] [Related]
22. The Shape of the Glucose Response Curve During an Oral Glucose Tolerance Test Heralds Biomarkers of Type 2 Diabetes Risk in Obese Youth.
Kim JY; Michaliszyn SF; Nasr A; Lee S; Tfayli H; Hannon T; Hughan KS; Bacha F; Arslanian S
Diabetes Care; 2016 Aug; 39(8):1431-9. PubMed ID: 27293201
[TBL] [Abstract][Full Text] [Related]
23. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
Ikonomidis I; Pavlidis G; Thymis J; Birba D; Kalogeris A; Kousathana F; Kountouri A; Balampanis K; Parissis J; Andreadou I; Katogiannis K; Dimitriadis G; Bamias A; Iliodromitis E; Lambadiari V
J Am Heart Assoc; 2020 May; 9(9):e015716. PubMed ID: 32326806
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors.
Ohki T; Isogawa A; Toda N; Tagawa K
Clin Drug Investig; 2016 Apr; 36(4):313-9. PubMed ID: 26914659
[TBL] [Abstract][Full Text] [Related]
25. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial.
Inoue H; Morino K; Ugi S; Tanaka-Mizuno S; Fuse K; Miyazawa I; Kondo K; Sato D; Ohashi N; Ida S; Sekine O; Yoshimura M; Murata K; Miura K; Arima H; Maegawa H;
J Diabetes Investig; 2019 Jul; 10(4):1012-1021. PubMed ID: 30536746
[TBL] [Abstract][Full Text] [Related]
26. Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men.
Rask E; Olsson T; Söderberg S; Johnson O; Seckl J; Holst JJ; Ahrén B;
Diabetes Care; 2001 Sep; 24(9):1640-5. PubMed ID: 11522713
[TBL] [Abstract][Full Text] [Related]
27. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
[TBL] [Abstract][Full Text] [Related]
28. The antidiabetic action of camel milk in experimental type 2 diabetes mellitus: an overview on the changes in incretin hormones, insulin resistance, and inflammatory cytokines.
Korish AA
Horm Metab Res; 2014 Jun; 46(6):404-11. PubMed ID: 24627103
[TBL] [Abstract][Full Text] [Related]
29. Incretins in fibrocalculous pancreatic diabetes: A unique subtype of pancreatogenic diabetes.
Ghosh I; Mukhopadhyay P; Das K; Anne M B; Ali Mondal S; Basu M; Nargis T; Pandit K; Chakrabarti P; Ghosh S
J Diabetes; 2021 Jun; 13(6):506-511. PubMed ID: 33247879
[TBL] [Abstract][Full Text] [Related]
30. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
Veltkamp SA; van Dijk J; Collins C; van Bruijnsvoort M; Kadokura T; Smulders RA
Clin Ther; 2012 Aug; 34(8):1761-71. PubMed ID: 22795925
[TBL] [Abstract][Full Text] [Related]
31. The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice.
Honda Y; Imajo K; Kato T; Kessoku T; Ogawa Y; Tomeno W; Kato S; Mawatari H; Fujita K; Yoneda M; Saito S; Nakajima A
PLoS One; 2016; 11(1):e0146337. PubMed ID: 26731267
[TBL] [Abstract][Full Text] [Related]
32. Clinical pharmacology study of ipragliflozin in Japanese patients with type 1 diabetes mellitus: A phase 2, randomized, placebo-controlled trial.
Kaku K; Isaka H; Toyoshima J; Sakatani T
Diabetes Obes Metab; 2019 Jun; 21(6):1445-1454. PubMed ID: 30821047
[TBL] [Abstract][Full Text] [Related]
33. Improved cardiometabolic risk factors in Japanese patients with type 2 diabetes treated with ipragliflozin: a pooled analysis of six randomized, placebo-controlled trials.
Kashiwagi A; Sakatani T; Nakamura I; Akiyama N; Kazuta K; Ueyama E; Takahashi H; Kosakai Y
Endocr J; 2018 Jul; 65(7):693-705. PubMed ID: 29848902
[TBL] [Abstract][Full Text] [Related]
34. Fasting hepatic insulin clearance reflects postprandial hepatic insulin clearance: a brief report.
Okura T; Nakamura R; Kitao S; Ito Y; Anno M; Matsumoto K; Shoji K; Matsuzawa K; Izawa S; Okura H; Ueta E; Kato M; Imamura T; Taniguchi SI; Yamamoto K
Diabetol Metab Syndr; 2023 Dec; 15(1):261. PubMed ID: 38115089
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium-glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus.
Saito M; Kaibara A; Kadokura T; Toyoshima J; Yoshida S; Kazuta K; Ueyama E
Br J Clin Pharmacol; 2019 Aug; 85(8):1808-1819. PubMed ID: 31026084
[TBL] [Abstract][Full Text] [Related]
36. Effect of 24-week treatment with ipragliflozin on proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes.
Nagai Y; Ohta A; Sada Y; Kato H; Tanaka Y
Expert Opin Pharmacother; 2017 Jan; 18(1):13-17. PubMed ID: 27841020
[TBL] [Abstract][Full Text] [Related]
37. Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1.
Sonne DP; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
Eur J Endocrinol; 2014 Oct; 171(4):407-19. PubMed ID: 24986531
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass.
Bojsen-Møller KN
Dan Med J; 2015 Apr; 62(4):B5057. PubMed ID: 25872541
[TBL] [Abstract][Full Text] [Related]
39. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
[TBL] [Abstract][Full Text] [Related]
40. Long-term efficacy of the sodium-glucose cotransporter 2 inhibitor, ipragliflozin, in a case of type A insulin resistance syndrome.
Nagashima S; Wakabayashi T; Saito N; Takahashi M; Okada K; Ebihara K; Ishibashi S
J Diabetes Investig; 2020 Sep; 11(5):1363-1365. PubMed ID: 32100949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
